Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in Oregon: - Providence Newberg Medical Center — Newberg, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Network
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Sites in Oregon: - Kaiser Sunnyside Medical Center — Clackamas, Oregon
- Rogue Valley Medical Center — Medford, Oregon
- Kaiser Permanente Northwest — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Oregon: - Clackamas Radiation Oncology Center — Clackamas, Oregon
- Legacy Mount Hood Medical Center — Gresham, Oregon
- Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carc…
Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT07011719
Sites in Oregon: - Compass Oncology, OR — Portland, Oregon
Phase 3 Recruiting Industry
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Sponsor: Xynomic Pharmaceuticals, Inc.
NCT ID: NCT03592472
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in Oregon: - Legacy Emanuel Children's Hospital — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
- Oregon Health & Science University (3485 S. Bond) — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Oregon: - Exelixis Clinical Site #51 — Portland, Oregon
Phase 1 Recruiting Industry
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalati…
Sponsor: HiberCell, Inc.
NCT ID: NCT06234605
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either di…
Sponsor: Nuvectis Pharma, Inc.
NCT ID: NCT05873686
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Sponsor: Novelty Nobility, Inc.
NCT ID: NCT06805825
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Oregon: - Legacy Emanuel Children's Hospital — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon: - Massive Bio SYNERGY-AI site — Portland, Oregon
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Oregon: - Oregon Health Sciences University — Portland, Oregon